Behavioural Brain Research, Journal Year: 2024, Volume and Issue: 466, P. 114995 - 114995
Published: April 9, 2024
Language: Английский
Neural Regeneration Research, Journal Year: 2023, Volume and Issue: 19(1), P. 100 - 115
Published: April 13, 2023
The current therapeutic drugs for Alzheimer's disease only improve symptoms, they do not delay progression. Therefore, there is an urgent need new effective drugs. underlying pathogenic factors of are clear, but neuroinflammation can link various hypotheses disease; hence, targeting may be a hope treatment. Inhibiting inflammation restore neuronal function, promote neuroregeneration, reduce the pathological burden disease, and or even reverse symptoms disease. This review focuses on relationship between reports mechanisms characteristics small-molecule (e.g., nonsteroidal anti-inflammatory drugs, neurosteroids, plant extracts); macromolecule peptides, proteins, gene therapeutics); nanocarriers lipid-based nanoparticles, polymeric nanoemulsions, inorganic nanoparticles) in treatment also makes recommendations prospective development strategies based
Language: Английский
Citations
15
International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(17), P. 13294 - 13294
Published: Aug. 27, 2023
The comprehensive narrative review conducted in this study delves into the mechanisms of communication and action at molecular level human organism. addresses complex mechanism involved microbiota-gut-brain axis as well implications alterations microbial composition patients with neurodegenerative diseases. pathophysiology diseases neuronal loss or death is analyzed, main metabolites bidirectional through axis. In addition, interventions targeting gut microbiota restructuring fecal transplantation use psychobiotics-pre- pro-biotics-are evaluated an opportunity to reduce symptomatology associated neurodegeneration these pathologies. This provides valuable information facilitates a better understanding neurobiological be addressed treatment
Language: Английский
Citations
14
Psychopharmacology, Journal Year: 2024, Volume and Issue: 241(7), P. 1329 - 1343
Published: Feb. 27, 2024
Language: Английский
Citations
6
Scientific Reports, Journal Year: 2024, Volume and Issue: 14(1)
Published: Feb. 2, 2024
Abstract Amlexanox is an anti-inflammatory and anti-allergic agent used clinically for the treatment of aphthous ulcers, allergic rhinitis, asthma. Recent studies have demonstrated that amlexanox, a selective inhibitor IkB kinase epsilon (IKKε) TANK-binding 1 (TBK1), suppresses range diseases or inflammatory conditions, such as obesity-related metabolic dysfunction type 2 diabetes. However, effects amlexanox on neuroinflammatory responses to not yet been comprehensively studied. In this study, we investigated novel therapeutic effect LPS-induced neuroinflammation in vivo , intraperitoneal injection markedly reduced IKKε levels, proinflammatory cytokines, microglial activation, evidenced by ionized calcium-binding adapter molecule (Iba1) immunostaining. Furthermore, significantly cytokines chemokines bone marrow-derived macrophages (BMDM), murine BV2, human HMC3 cells. This data provided considerable evidence can be preventive curative therapy neurodegenerative diseases. terms mechanism aspects, our results action BV2 cells was through downregulation NF-κB STAT3 signaling pathways. addition, combination SPI (a inhibitor) showed high efficiency inhibiting production neurotoxic pro-inflammatory mediators. Overall, provide rational insights into mechanisms potential strategy neuroinflammation-related
Language: Английский
Citations
6
Behavioural Brain Research, Journal Year: 2024, Volume and Issue: 466, P. 114995 - 114995
Published: April 9, 2024
Language: Английский
Citations
5